chevron_leftBack
As of 15 June 2026, CervoMed Inc. has a market cap of $33.79M USD, ranking #33415 globally and #4710 in the United States.
It ranks #7632 in the Industrials sector, and #926 in the Specialty Business Services industry.
Key Stats
Market Cap
$33.79MUSD
Enterprise Value
$13.12MUSD
Revenue (TTM)
$4.01MUSD
Net Income (TTM)
-$26.97MUSD
PS Ratio
8.5
PB Ratio
1.9
Company Profile
Country (HQ)
Sector
Industrials
Industry
Specialty Business Services
CEO
John Alam
open_in_new
Employees
15
Founded
2001
Website
cervomed.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -1.6% | -7.4% | -1.9% | -32% | -46% | -60% |
News
Loading...
CRVO Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
CRVO
CervoMed Inc
ISIN: US15713L1098
Shares Out.:
Shares Outstanding:
9.259M1
Shares Float:
4.796M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
3.65 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About CervoMed Inc.
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38α. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: CTAS
|
$69.6B
206K%
|
36.8
|
|
NASDAQ: PYPL
|
$45.83B
136K%
|
9.4
|
|
NYSE: XYZ
|
$41.37B
122K%
|
33.1
|
|
NASDAQ: FISV
|
$33.06B
98K%
|
9.8
|
|
NYSE: ROL
|
$26.64B
79K%
|
51.1
|
|
NYSE: CPAY
|
$20.3B
60K%
|
20.7
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: SHOP
|
$158.14B
468K%
|
129.8
|
|
STO: VSURE
|
$132.68B
393K%
114.8B EUR
|
-
|
|
LSE: REL
|
$63.78B
189K%
47.6B GBP
|
23.9
|
|
|
T
NEO: TRI
|
$41.8B
124K%
56.91B CAD
|
-
|
|
AMS: UMG
|
$41.12B
122K%
35.58B EUR
|
23.4
|
|
AMS: ADYEN
|
$34.79B
103K%
30.1B EUR
|
28.4
|
chevron_leftBack